Sugi Predict

Sugi Predict / Compounds / SCHEMBL669362

SCHEMBL669362

SCHEMBL669362

CC1CCCCC1C(=O)Cl

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 4/20 0.60
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA4 P22748 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TAS1R3 Q7RTX0 4/20 0.33
▸ TAS1R1 Q7RTX1 3/20 0.33
▸ TAS1R2 Q8TE23 3/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ OPRM1 P35372 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ CES2 O00748 1/20 0.31
▸ CES1 P23141 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ RECQL P46063 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16604831 0.95 — —
SCHEMBL11627899 0.87 — —
SCHEMBL11199858 0.81 EPHX1 (0.40) EPHX1SMN1; SMN2MEN1KMT2ACES2
SCHEMBL11199862 0.81 EPHX1 (0.40) EPHX1SMN1; SMN2MEN1KMT2ACES2
SCHEMBL8191588 0.81 EPHX1 (0.40) EPHX1SMN1; SMN2MEN1KMT2ACES2
SCHEMBL895753 0.81 EPHX1 (0.40) EPHX1SMN1; SMN2MEN1KMT2ACES2
SCHEMBL27657024 0.79 EPHX1 (0.65) EPHX1CA1CA2CA4SMN1; SMN2
SCHEMBL8229502 0.77 EPHX1 (0.62) EPHX1CA1CA2CA4SMN1; SMN2
SCHEMBL11930055 0.77 EPHX1 (0.62) EPHX1CA1CA2CA4SMN1; SMN2
SCHEMBL20832552 0.77 EPHX1 (0.44) EPHX1CA1CA2CA4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010115869-A1 PROPOFOL PHOSPHONYL DERIVATIVES, SYNTHESIS, AND USE IN LONG ACTING FORMULATIONS SEPS PHARMA N.V. (BE) 2010-10-14 — — WO claimed
US-20230082167-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC (US) 2023-03-16 — — US disclosed
EP-1592738-B1 RESIN COMPOSITIONS CIBA HOLDING INC (CH) 2020-07-29 — — EP disclosed
US-10597378-B2 Tetrahydroisoquinolines for use as MOR/NOP dual agonists NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2020-03-24 — — US disclosed
US-20190077786-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2019-03-14 — — US disclosed
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2018-10-11 — — US disclosed
US-20160326181-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2016-11-10 — — US disclosed
US-20160326181-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2016-11-10 — — US disclosed
US-20160326181-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2016-11-10 — — US disclosed
EP-3031324-A2 TRICYCLIC KINASE INHIBITORS AbbVie Inc. (US) 2016-06-15 — — EP disclosed
WO-2004072168-A2 RESIN COMPOSITIONS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-08-26 — — WO disclosed
EP-1397363-A1 5-ETHYL-IMIDAZOTRIAZINONES Bayer HealthCare AG (DE) 2004-03-17 — — EP disclosed
WO-2002098880-A1 5-ETHYL-IMIDAZOTRIAZINONES BAYER HEALTHCARE AG (DE) 2002-12-12 — — WO disclosed
CN-1372548-A Heterocyclic compound and medical use thereof AJINOMOTO KK (JP) 2002-10-02 — — CN disclosed
US-20020133005-A1 Heterocyclic compounds and medical use thereof AJINOMOTO CO., INC. (JP) 2002-09-19 — — US disclosed
EP-1193255-A1 HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF Ajinomoto Co., Inc. (JP) 2002-04-03 — — EP disclosed
EP-0128654-B1 GEM-DIAMINOALKANE DERIVED SWEETENERS CUMBERLAND PACKING CORPORATION (US) 1989-10-18 — — EP disclosed
EP-0242896-A2 Novel intermediates useful in the production of gem-diaminoalkane derived sweeteners CUMBERLAND PACKING CORPORATION (US) 1987-10-28 — — EP disclosed
US-4571345-A 1,1-Diaminoalkane derived sweeteners CUMBERLAND PACKING CORP. (US) 1986-02-18 — — US disclosed
EP-0128654-A2 Gem-diaminoalkane derived sweeteners CUMBERLAND PACKING CORPORATION (US) 1984-12-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10597378-B2 Tetrahydroisoquinolines for use as MOR/NOP dual agonists OPRL1, OPRM1, OPRK1 EPHX1 1413/4885CA1 4348/4885CA2 4708/4885
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 EPHX1 1193/4885CA1 1741/4885CA2 1885/4885
US-20190077786-A1 HETEROCYCLIC COMPOUNDS AND USE THEREOF OPRM1, OPRL1, OPRK1 EPHX1 1298/4885CA1 3079/4885CA2 4214/4885
US-20160326181-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 EPHX1 1193/4885CA1 1741/4885CA2 1885/4885
US-20020133005-A1 Heterocyclic compounds and medical use thereof NFKBIA, CHUK, RELA EPHX1 1225/4885CA1 1388/4885CA2 1001/4885
US-20230082167-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 EPHX1 1193/4885CA1 1741/4885CA2 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.